Evidence map›Paper›PMID 40771920›Full record

ArticleFrontiers in pharmacology2025

The effects of benralizumab on lung volume changes during exercise in experimental setting in severe asthmatics: a pilot study.

Alida Benfante, Alessandra Tomasello, Lorena Gentile, Alessia Leonarda Lisotta, Paola Marasà, Salvatore Battaglia, Nicola Scichilone

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alida BenfanteDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.
Alessandra TomaselloDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.
Lorena GentileDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.
Alessia Leonarda LisottaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.
Paola MarasàDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.
Salvatore BattagliaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.
Nicola ScichiloneDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University of Palermo, Palermo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The most severe forms of asthma are characterised by the occurrence of dyspnoea on exertion, impacting on daily activities and quality of life. It has been demonstrated that dynamic hyperinflation (DH) during exercise represents a mechanism of physical activity limitation in severe asthmatics. Inspiratory capacity (IC) at rest may be an indicator of static hyperinflation, and the change in IC during exercise can be regarded as a marker of DH. The study aims to assess whether Benralizumab is able to improve IC and to reduce DH. Materials and methods: A pilot study on severe asthmatics was conducted. Assessments of asthma control and quality of life, lung function evaluation and 6-min walk test (6MWT) were carried out on the day of the first drug administration (T Results: Twelve severe asthmatics were recruited. Significant improvements of dynamic volumes, asthma control and quality of life were observed after anti IL-5R treatment. At T Discussion: These findings show the effect of Benralizumab in improving IC during exercise. The disappearance of DH provides a potential explanation for the beneficial effect of biologics in severe asthmatics.

Indexed as

benralizumabdynamic hyperinflationexerciseinspiratory capacitysevere asthma

Identifiers

PMID40771920
PMCPMC12325302

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.